Analysts Set Expectations for Apyx Medical Q2 Earnings

Apyx Medical Corporation (NASDAQ:APYX) – HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Apyx Medical in a report issued on Monday, July 13th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. HC Wainwright also issued estimates for Apyx Medical’s Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.21) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.19) EPS.

A number of other equities analysts have also issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Apyx Medical presently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Apyx Medical Stock Down 0.9%

Shares of APYX stock opened at $4.22 on Wednesday. Apyx Medical has a 12 month low of $1.59 and a 12 month high of $5.08. The company has a quick ratio of 4.79, a current ratio of 5.80 and a debt-to-equity ratio of 2.68. The firm has a market cap of $176.86 million, a PE ratio of -19.18 and a beta of 1.37. The stock has a 50 day moving average of $4.19 and a 200-day moving average of $3.89.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. The firm had revenue of $12.49 million for the quarter, compared to analyst estimates of $10.53 million. Apyx Medical had a negative return on equity of 88.47% and a negative net margin of 16.40%.

Institutional Trading of Apyx Medical

Institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC increased its position in shares of Apyx Medical by 19.1% during the fourth quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after purchasing an additional 636,043 shares during the period. Vanguard Group Inc. boosted its stake in Apyx Medical by 3.6% during the third quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock worth $3,272,000 after buying an additional 53,175 shares in the last quarter. AIGH Capital Management LLC acquired a new stake in Apyx Medical during the fourth quarter worth $3,867,000. Silverberg Bernstein Capital Management LLC increased its holdings in Apyx Medical by 0.8% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock valued at $3,842,000 after buying an additional 8,067 shares during the period. Finally, Sei Investments Co. increased its holdings in Apyx Medical by 298.6% in the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after buying an additional 448,174 shares during the period. Institutional investors and hedge funds own 55.33% of the company’s stock.

Key Apyx Medical News

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: HC Wainwright initiated coverage on Apyx Medical with a Buy rating and a $7.00 price target, suggesting significant upside potential. Benzinga
• Neutral Sentiment: The firm’s updated model calls for continued quarterly losses through 2026 and 2027, including FY2026 EPS of ($0.21) and FY2027 EPS of ($0.19), which reflects ongoing profitability challenges.
• Neutral Sentiment: HC Wainwright’s quarterly estimates are broadly consistent with a gradual improvement trend, but they still point to negative EPS in each forecast period.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.